Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

Teladoc Health, Inc.
Next earnings Jul 27, 2026 (after close) · consensus $-0.26 EPS, $627M rev
Last earnings -0.8% on 2026-04-29
Revenue declined -1.5% YoY.
Teladoc Health, Inc. shows $2.53B in FY2025 revenue (-1.5% YoY), a -7.9% net margin, and -14.5% ROE.
Sources: SEC EDGAR (CIK 0001477449, latest 10-Q filed 2026-04-30) · EODHD · as of 6/23/2026, 11:24:12 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $2.03B | $2.41B | $2.60B | $2.57B | $2.53B |
| Gross profit | — | — | — | — | — |
| Operating income | -$266M | -$13.7B | -$249M | -$1.02B | -$263M |
| Net income | -$429M | -$13.7B | -$220M | -$1.00B | -$200M |
| Diluted EPS | -$2.73 | -$84.60 | -$1.34 | -$5.87 | -$1.14 |
| Net margin | -21.1% | -567.5% | -8.5% | -39.0% | -7.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 8 sales
| 2026-06-11 | DIVITA CHARLES III CHIEF EXECUTIVE OFFICER | Sell | 18.1K @ $6.94 | $125K |
| 2026-06-10 | DIVITA CHARLES III CHIEF EXECUTIVE OFFICER | Exercise | 3.64K | |
| 2026-06-10 | DIVITA CHARLES III CHIEF EXECUTIVE OFFICER | Exercise | 39.2K | |
| 2026-06-03 | Rodrigues Fernando M. President of BetterHelp | Sell | 9.57K @ $7.40 | $70.8K |
| 2026-06-02 | Rodrigues Fernando M. President of BetterHelp | Sell | 5.68K @ $7.63 | $43.3K |
| 2026-06-02 | Vandervoort Adam C CHIEF LEGAL OFFICER, SECRETARY | Sell | 7.91K @ $7.63 | $60.3K |
| 2026-06-02 | Nueno Carlos President, International | Sell | 6.20K @ $7.63 | $47.3K |
| 2026-06-02 | DIVITA CHARLES III CHIEF EXECUTIVE OFFICER | Sell | 19.1K @ $7.63 | $146K |
| 2026-06-02 | Catapano Joseph Ronald Chief Accounting Officer | Sell | 284.00 @ $7.63 | $2.17K |
| 2026-06-02 | Bliss Kelly President, U.S. Group Health | Sell | 7.68K @ $7.63 | $58.6K |
| 2026-06-01 | Rodrigues Fernando M. President of BetterHelp | Exercise | 5.49K | |
| 2026-06-01 | Rodrigues Fernando M. President of BetterHelp | Exercise | 1.04K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.